Coral Medroxyprogesterone Acetate Coral Medroxyprogesterone Acetate

X
[{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bill & Melinda Gates Foundation, Children\u2019s Investment Fund Foundation, Pfizer and Becton, Dickinson & Company Expand Partnership for Greater Access to Injectable Contraceptive for Women in Low- and Lower-Middle-Income Countries","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Medroxyprogesterone

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030.

            Lead Product(s): Medroxyprogesterone Acetate

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Sayana Press

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration August 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Close
            4
            Post Enquiry
            POST ENQUIRY